

F.1 amnd
enzyme activity at said locations of the mammalian skin, wherein the mammalian skin is selected from the group consisting of a human and a mouse.

Please enter the following new claims:

F.2

- 41. (New) The method of claim 40, wherein the composition is delivered by topical application.
- 42. (New) The method of claim 40, wherein the composition is delivered by intradermal injection.

Remarks

Entry of this paper and consideration of the subject application in view thereof are respectfully requested.

In the Final Office Action of July 31, 2002, claim 40 and other claims were rejected as, among other things, obvious over Yoon et al., 1996, Proc. Natl. Acad. Sci., 93:2071-2076 and Alexeev et al., 1998, Nature Biotechnology 16:1343-1346, in view of Uttam et al., 1996, Proc. Natl. Acad. Sci., 93:9079-9084, Christiano et al., 1994, Proc. Natl. Acad. Sci., 91:3549-3553 and Cole-Strauss et al., 1996, Science, 273:1386-1389.

The Advisory Action of January 17, 2003 notes that the amendment filed in response to the Final Office Action of July 31, 2002 was not entered for reasons stated under section 2 (a)-(c).

Without conceding the validity of the Examiner's bases for the claim rejections, and solely for purposes of expediting prosecution of this Application, Applicant has made certain claim amendments herein. Particularly, claims 1-39 have been canceled. These cancellations are made without prejudice to the assertion of additional claims in a continuation application. No new matter is added.

At the outset, Applicant respectfully submits that none of the claims (those pending or canceled) are obvious. As asserted in the April 26, 2002 and December 27, 2002 responses, there is no suggestion for Applicant's method in the cited prior art. Further, in the amendment and response filed on April 26, 2002, Applicant also pointed to certain unexpected results. In